Supplemental Table 1. Therapeutic regimens for IgAN-AS and non-IgAN patients. Values are n (%) unless otherwise specified.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Total (n = 62) | IgAN-AS patients(n = 46) | non-IgAN patients (n = 16) | P |
| Immunosuppressant | 27 (43.5) | 21 (45.7) | 6 (37.5) | .57 |
| Leflunomide | 19 (30.6) | 18 (39.1) | 1(6.3) | .01 |
| Mycophenolate mofetil | 7(11.3) | 5 (10.9) | 2(12.5) | >.99 |
| Tacrolimus | 3 (4.8) | 0 | 3 (18.8) | .003 |
| Cyclophosphamide | 4 (6.5) | 2 (4.3) | 2 (12.5) | .27 |
| Oral glucocorticoid | 30 (48.4) | 20 (43.5) | 10 (62.5) | .19 |
| Glucocorticoid alone | 4 (6.5) | 1 (2.2) | 3 (18.8) | .02 |
| Glucocorticoid +IMS | 17(27.4) | 11 (23.9) | 6 (37.5) | .20 |
| ARB/ACEI | 37 (59.7) | 31 (67.4) | 6 (37.5) | .04 |
| ARB/ACEI alone | 7 (11.3) | 4 (8.7) | 3 (18.8) | .36 |

Abbreviations: IgAN-AS: IgA nephropathy related to AS; IMS, immunosuppressant; ARB, aldosterone receptor antagonist; ACEI, angiotensin-converting enzyme inhibitor.